(S (NP (NP (JJ Modern) (NNS treatments)) (PP (IN for) (NP (NP (NNP Type) (CD 1) (NNS diabetes)) (PRN (-LRB- -LRB-) (NP (NNP T1D)) (-RRB- -RRB-))))) (VP (NN use) (NP (NP (NNS devices)) (VP (VBN known) (PP (IN as) (NP (NP (JJ artificial) (NN pancreata)) (PRN (-LRB- -LRB-) (NP (NNP APs)) (-RRB- -RRB-))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP combine) (NP (DT an) (NN insulin) (NN pump)) (PP (IN with) (NP (NP (NP (DT a) (JJ continuous) (NN glucose) (NN monitor)) (PRN (-LRB- -LRB-) (NP (NNP CGM)) (-RRB- -RRB-))) (VP (NN operating) (PP (IN in) (NP (DT a) (JJ closed-loop) (NN manner)))))) (S (VP (TO to) (VP (VB control) (NP (NN blood) (NN glucose) (NNS levels)))))))))) (. .))
(S (PP (IN In) (NP (NN practice))) (, ,) (NP (NP (NP (JJ poor) (NN performance)) (PP (IN of) (NP (NNP APs)))) (PRN (-LRB- -LRB-) (NP (JJ frequent) (ADJP (NN hyper-) (CC or) (JJ hypoglycemic)) (NNS events)) (-RRB- -RRB-))) (VP (VBZ is) (ADJP (JJ common) (RB enough)) (PP (IN at) (NP (DT a) (NN population) (NN level))) (SBAR (IN that) (S (NP (JJ many) (NNP T1D) (NNS patients)) (VP (VB modify) (NP (NP (DT the) (NN algorithms)) (PP (IN on) (NP (VBG existing) (NNP AP) (NNS systems)))) (PP (IN with) (NP (JJ unregulated) (JJ open-source) (NN software))))))) (. .))
(S (S (ADVP (RB Anecdotally)) (, ,) (NP (NP (DT the) (NNS patients)) (PP (IN in) (NP (DT this) (NN group)))) (VP (VBP have) (VP (VBN shown) (NP (NP (JJ superior) (NNS outcomes)) (PP (VBN compared) (PP (IN with) (NP (NP (NN standard)) (PP (IN of) (NP (NN care)))))))))) (, ,) (RB yet) (S (NP (PRP we)) (VP (VBP do) (RB not) (VP (VB understand) (SBAR (WHADJP (WRB how) (JJ safe)) (S (NP (DT any) (NNP AP) (NN system)) (VP (VBZ is)))) (SBAR (IN since) (S (NP (JJ adverse) (NNS outcomes)) (VP (VBP are) (ADJP (JJ rare)))))))) (. .))
(S (PP (IN In) (NP (DT this) (NN paper))) (, ,) (NP (PRP we)) (VP (VBP construct) (NP (NP (JJ generative) (NNS models)) (PP (IN of) (NP (NP (JJ individual) (NNS patients) (POS â€º)) (NX (NX (JJ physiological) (NNS characteristics)) (CC and) (NX (VBG eating) (NNS behaviors))))))) (. .))
(S (NP (PRP We)) (ADVP (RB then)) (VP (VB couple) (NP (DT these) (NNS models)) (PP (IN with) (NP (NP (DT a) (NNP T1D) (NN simulator)) (VP (VBD approved) (PP (IN for) (NP (JJ pre-clinical) (NNS trials))) (PP (IN by) (NP (DT the) (NNP FDA))))))) (. .))
(S (PP (VBN Given) (NP (DT the) (NN ability) (S (VP (TO to) (VP (VB simulate) (NP (JJ patient) (NNS outcomes)) (ADVP (JJ in-silico))))))) (, ,) (NP (PRP we)) (VP (VBP utilize) (NP (NP (NNS techniques)) (PP (IN from) (NP (JJ rare-event) (NN simulation) (NN theory)))) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (ADVP (RB efficiently)) (VB quantify) (NP (NP (DT the) (NN performance)) (PP (IN of) (NP (DT a) (NN device))) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (DT a) (JJ particular) (NN patient))))))))))) (. .))
(S (PP (IN In) (NP (NN practice))) (NP (PRP$ our) (NN toolchain)) (VP (VBZ enables) (NP (NP (NNS estimates)) (PP (IN of) (NP (NP (DT the) (NN likelihood)) (PP (IN of) (NP (JJ hypoglycemic) (NNS events)))))) (PP (IN with) (NP (ADJP (NP (NP (RB approximately) (DT an) (NN order)) (PP (IN of) (NP (NN magnitude)))) (JJR fewer)) (NNS simulations)))) (. .))
